OBJECTIVES: Combined immunochemotherapy with interleukin 2 (IL-2), interferon alpha (IFN-alpha), and 5-fluorouracil (5-FU) is an established first-line therapy for metastatic renal cell carcinoma (RCC). However, data on histologic parameters predictive of clinical benefit are rare. In this study, we evaluated the response to immunochemotherapy in the main histologic subtypes of renal cell carcinoma and performed a subgroup analysis of inoperable patients. METHODS: From 164 patients treated with one or two cycles of combined immunochemotherapy, radical nephrectomy had revealed 22 cases of papillary RCC (pRCC; 13.4%) and 131 cases of clear cell RCC (ccRCC; 79.9%). In the remaining 11 (6.7%) their disease was inoperable. The overall response rates were evaluated according to World Health Organization criteria. RESULTS: For ccRCC and inoperable disease, responses of 34.4% and 27.3% after one cycle and 28.8% and 16.7% after two cycles, respectively, were noted. In contrast, no patient with pRCC showed any response after two cycles of combined immunochemotherapy. CONCLUSIONS: No objective response was seen in patients with pRCC. Hence, the use of immunotherapeutic agents must be questioned in this histologic subtype.
OBJECTIVES: Combined immunochemotherapy with interleukin 2 (IL-2), interferon alpha (IFN-alpha), and 5-fluorouracil (5-FU) is an established first-line therapy for metastatic renal cell carcinoma (RCC). However, data on histologic parameters predictive of clinical benefit are rare. In this study, we evaluated the response to immunochemotherapy in the main histologic subtypes of renal cell carcinoma and performed a subgroup analysis of inoperable patients. METHODS: From 164 patients treated with one or two cycles of combined immunochemotherapy, radical nephrectomy had revealed 22 cases of papillary RCC (pRCC; 13.4%) and 131 cases of clear cell RCC (ccRCC; 79.9%). In the remaining 11 (6.7%) their disease was inoperable. The overall response rates were evaluated according to World Health Organization criteria. RESULTS: For ccRCC and inoperable disease, responses of 34.4% and 27.3% after one cycle and 28.8% and 16.7% after two cycles, respectively, were noted. In contrast, no patient with pRCC showed any response after two cycles of combined immunochemotherapy. CONCLUSIONS: No objective response was seen in patients with pRCC. Hence, the use of immunotherapeutic agents must be questioned in this histologic subtype.
Authors: Nathan M Mollberg; Nicholas B Johnson; Shan-Chinga Ying; Khaled Abdelhady; Malek G Massad; Doreen E Chung Journal: Can Urol Assoc J Date: 2012-04 Impact factor: 1.862
Authors: Thomas Steiner; Hartmut Kirchner; Michael Siebels; Christian Doehn; Hans Heynemann; Zoltan Varga; Detlef Rohde; Joerg Schubert; Dieter Jocham; Christian Stief; Paolo Fornara; Rainer Hofmann; Stefan Loening; Jan Roigas Journal: J Cancer Res Clin Oncol Date: 2009-12-12 Impact factor: 4.553
Authors: Yoshiyuki Takahashi; Nanae Harashima; Sachiko Kajigaya; Hisayuki Yokoyama; Elena Cherkasova; J Philip McCoy; Ken-Ichi Hanada; Othon Mena; Roger Kurlander; Abdul Tawab; Tawab Abdul; Ramaprasad Srinivasan; Andreas Lundqvist; Elizabeth Malinzak; Nancy Geller; Michael I Lerman; Richard W Childs Journal: J Clin Invest Date: 2008-03 Impact factor: 14.808
Authors: A J Schrader; S Rauer-Bruening; P J Olbert; A Hegele; J Rustemeier; N Timmesfeld; Z Varga; R Hofmann Journal: J Cancer Res Clin Oncol Date: 2008-11-21 Impact factor: 4.553
Authors: Jill M Hagenkord; Anil V Parwani; Maureen A Lyons-Weiler; Karla Alvarez; Robert Amato; Zoran Gatalica; Jose M Gonzalez-Berjon; Leif Peterson; Rajiv Dhir; Federico A Monzon Journal: Diagn Pathol Date: 2008-11-06 Impact factor: 2.644